The local medical sector is excited with the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for managing obesity. This medication https://social-lyft.com/story11876736/retatrutide-australia-a-potential-solution-for-weight-loss